Search results
Retiree calls out Sask. gov't for not communicating changes to accessing COVID-19 drug Paxlovid
CBC via Yahoo News· 7 hours agoWhen Greg Pletz contracted COVID-19 in mid-May, he called the Saskatchewan 811 HealthLine and was...
FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine
MedPage Today· 2 days agoIn the briefing document, the FDA staff gave a brief history of coronavirus vaccines, noting that...
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 22 hours agoIf you've been on the sidelines, now could be a great time to buy the stock. Shares of Pfizer have...
Pfizer's Options Frenzy: What You Need to Know - Pfizer (NYSE:PFE)
Benzinga· 6 days agoInsights into Volume & Open Interest Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer ...
The Income Investor's Dream Team: 7 Sturdy Dividend Stocks Yielding 6%
InvestorPlace· 21 hours agoThe most obvious reason investors should buy high-yield dividend stocks is that they provide income....
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 5 days agoQ1 Earnings & Sales Top, EPS Guidance Raised Pfizer’s first-quarter results were strong as it beat...
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 5 days agoAccording to the data, 61% of patients taking Lorbrena had no disease progression after five years,...
Pfizer says tweaked COVID-19 shots boost omicron protection
KRGV Rio Grande Valley· 6 days agoPfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 5 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 5 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.